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Summary 
The hypothesis underlying this study is that variations in genes involved 
in methionine metabolism may contribute to genetic susceptibility for 
early-onset ischaemic stroke. We investigated 58 polymorphisms in 
AHCY, BHMT, BHMT2, CBS, ENOSF1, FOLH1, MTHFD1, MTHFR, MTR, 
MTRR, NNMT, PON1, PON2, SLC19A1, SHMT1, TCN2, TYMS genes on 
genomic DNA from 501 young patients who survived ischaemic stroke 
and 1,211 sex and age comparable controls. Genotype distribution was 
significantly different between patients and controls for the following 
SNPs: rs10037045 BHMT, rs682985 BHMT2, rs1051319 CBS, rs202680 
FOLH1, rs2274976 MTHFR, rs1979277 SHMT1, rs20721958 TCN2. On 
multiple logistic regression analysis adjusted for traditional risk factors, 
rs10037045 BHMT, rs682985 BHMT2, rs1051319 CBS, and rs202680 
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FOLH1 remained independent risk factors for stroke. After haplotype re-
construction, generalised linear model analyses adjusted for traditional 
risk factors and using the FDR multiple testing correction showed sig-
nificant associations between ischaemic stroke and BHMT, CBS, FOLH1, 
MTR, PON2, TCN2 and TYMS haplotypes. This study identifies signifi-
cant genetic associations between premature ischaemic stroke and ha-
plotypes in BHMT, CBS, FOLH1, MTR, PON2, TCN2 and TYMS genes in-
volved in methionine metabolism. 
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Introduction 
Since 1969 (1), substantial evidence has been accumulated linking 
high homocysteine (Hcy) levels in blood to the risk of cardiovascu-
lar disease (2, 3). Raised concentrations of Hcy have been sug-
gested to be a modifiable, independent risk factor for coronary ar-
tery disease, stroke, and deep-vein thrombosis (4–7). 
Hcy is a branch-point intermediate of methionine metabolism, 
which can be further metabolised via two alternative pathways: de-
graded irreversibly through the transsulfuration pathway or re-
methylated to methionine by the remethylation pathway. Both 
pathways are B-vitamin-dependent. Genetic defects in genes en-
coding enzymes involved in Hcy metabolism, or depletion of im-
portant cofactors or (co)substrates for those enzymes – including 
folate, vitamin B(12) and vitamin B(6) – may result in elevated 
plasma concentrations of Hcy (8, 9). A recent review showed that 
23 genes could modulate Hcy levels and that 112 genes are modu-
lated epigenetically by hyperhomocysteinaemia (10). Several poly-
morphisms in genes coding for enzymes involved in the methion-
ine metabolism have also been suspected to be associated with hy-
perhomocysteinaemia. Pertaining to some polymorphisms, e.g. 
C677T and A1298C in 5,10-methylenetetrahydrofolate reductase 
(MTHFR) gene, A2756G in 5-methyltetrahydrofolate-homocys-
teine methyltransferase (MTR) gene, A66G in 5-methyltetrahy-
drofolate-homocysteine methyltransferase reductase (MTRR) 
gene, T163A in paraoxonase 1 (PON1) gene, G80A in solute carrier 
family 19 (folate transporter), member 1 (SLC19A1) gene, C776G 
in transcobalamin II (TCN2), 6bp ins del in thymidylate synthe-
tase (TYMS) gene, contrasting data are available (10). For C677T 
and A1298C MTHFR polymorphisms, the rare allele is associated 
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with reduced enzymatic activity (11, 12). Furthermore, methion-
ine metabolism plays a crucial role in the methylation of a wide 
variety of essential biological substances, including phospholipids, 
proteins, neurotransmitters, and DNA. Therefore, besides altering 
levels of the toxic intermediate Hcy and of Hcy-thiolactone (13), 
polymorphisms/haplotypes of genes involved in the methionine 
metabolism might determine the improper function of many 
other biological processes, such as DNA methylation and, hence, 
the genetic stability and the expression of several important genes 
(14). 
Due to the complexity of genetic mechanisms implicated in 
methionine metabolism perturbation, this study aimed to evaluate 
the genetic susceptibility for premature ischaemic stroke conferred 
by 58 polymorphisms in 17 genes [adenosylhomocysteinase 
(AHCY), betaine-homocysteine methyltransferase (BHMT), be-
taine-homocysteine methyltransferase 2 (BHMT2), cystathion-
ine-beta-synthase (CBS), enolase superfamily member 1 
(ENOSF1), folate hydrolase 1 (FOLH1), methylenetetrahydro-
folate dehydrogenase (MTHFD1), MTHFR, MTR, MTRR, nicoti-
namide N-methyltransferase (NNMT), PON1, paraoxonase 2 
(PON2), SLC19A1, serine hydroxymethyltransferase 1 (SHMT1), 
TCN2, TYMS] coding for enzymes involved in the methionine me-
tabolism. Polymorphisms selection was performed to address two 
objectives: to study genetic variants for which consistent or con-
trasting literature data were available and to reconstruct haplo-
types that could permit us a better evaluation of the effect of gene 
alleles in determining susceptibility to early-onset ischaemic 
stroke. 
Materials and methods 
Study population 
Five hundred one unrelated Caucasian young adults (<65 years) 
who were referred to the a) Angelo Bianchi Bonomi Hemophilia 
and Thrombosis Center of the University of Milan, Italy, and b) to 
Department of Neurology, Sapienza University, Sant'Andrea Hos-
pital, Rome, Italy, for thrombophilia screening after a first is-
chaemic stroke were enrolled in this study. Patient and control 
populations were in part previously investigated in relation to 
polymorphisms of genes encoding procoagulant and inflamma-
tory factors (15). The median time interval between the ischaemic 
stroke and blood sampling was six months (range one month to 10 
years); 75% of patients had blood sampled within two years and 
64% within one year after the event. Clinical records were reviewed 
and when the type of stroke was not specified, neurologists who 
took care of the patients during the acute phase were contacted. 
The clinical diagnosis was objectively confirmed by computed to-
mography scans or magnetic resonance or magnetic resonance an-
giography and intra-arterial angiography. According to TOAST 
classification, 13.4% of enrolled patients were classified as large ar-
tery stroke, 5.2% as cardioembolic, 16.5% as small artery (lacu-
nar), 53.5% as undetermined aetiology and 11.4% as other deter-
mined aetiology stroke. All patients underwent a cardiologic 
evaluation and transthoracic echocardiography and Doppler 
examination of the neck vessels. 
One thousand two-hundred eleven healthy unrelated Cau-
casian subjects comparable for age and gender were chosen from 
the whole population of controls made of partners and friends 
who accompanied patients to the Centre in the same period as pa-
tients and agreed to be investigated. Previous thrombosis in the 
controls was excluded using a validated structured questionnaire 
(16). The presence, at the time of stroke for patients and at the time 
of blood sampling for controls, of hypertension, hypercholestero-
laemia, diabetes mellitus, and smoking habit (at least five cigarettes 
daily) was recorded. 
The study was approved by the Institutional Review Board of 
the University of Milan, University of Rome and University of Flo-
rence and all subjects gave their informed consent to the study. 
DNA extraction 
Genomic DNA was isolated from peripheral blood by using Flex-
iGene kit (QIAGEN, Hilden, Germany). 
Genotyping 
We studied 58 single nucleotide polymorphism (SNPs) in 17 can-
didate genes involved in methionine metabolism (for gene se-
quences and oligonucleotides see our previous papers) (17, 18), ac-
cording to their demonstrated or putative function based on litera-
ture data, localization in the functional region and/or heterozygos-
ity values >0.30, extracted from dbSNP database 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=snp&cmd= 
search&term=). Thirteen genes (AHCY, BHMT, CBS, FOLH1, 
MTHFD1, MTHFR, MTR, MTRR, PON1, SLC19A1, SHMT1, 
TCN2, TYMS) were selected among 23 genes identified by litera-
ture mining that they modulate Hcy levels (10), and three genes 
(BHMT2, NNMT, PON2) were selected on the basis of their in-
volvement in the methionine metabolism, and one gene 
(ENOSF1) because we genotyped a SNP located at the 3'UTR of 
the ENOSF1 gene overlapping the 3’ end of the TYMS gene. SNPs 
information were assessed in dbSNP NCBI and ENSEMBL 
(http://www.ensembl.org/index.html) databases. 
SNPs were analysed by using GenomeLab SNPstream genotyp-
ing platform and software (Beckman Coulter, Fullerton, CA, USA) 
according to previously described protocols(17, 18). Briefly, in 
order to identify highly homologous and repetitive elements, ge-
nomic DNA sequences were subjected to BLAST search 
(http://www.ncbi.nlm.nih.gov/BLAST/). A specific software 
(http://www.autoprimer.com) to design the 12 pairs of primers for 
multiplex PCR and 12 tagged extension primers were used (see our 
previous papers) (17, 18). After multiplex polymerase chain reac-
tion (PCR) reaction, a multiplex primer extension reaction was 
performed. The hybridisation mix containing the primer exten-
sion products was added to the SNPware plate, so that each ex-
tended primer hybridise in a specific way to one of the unique 
probes arrayed in each well. The SNPware plate was analysed with 
the SNPstream array imager. Sample genotype data were auto-
matically generated. 
Hcy measurement 
Venous blood was collected after an overnight fasting from all sub-
jects. Total Hcy plasma levels were determined by an immunoassay 
method (FPIA, IMX system, Abbott). 
Data analysis 
Statistical analysis was performed using the SPSS package v11.5. 
The Hardy-Weinberg equilibrium was evaluated by the Chi2 test. 
Genotype distributions were compared between groups by Chi2 
analysis. We assessed the association between each polymorphism 
and stroke using different genetic models. The dominant model 
compares individuals with one or two rare alleles (heterozy-
gotes+homozygotes) with the baseline group of homozygous sub-
jects. The recessive model compares individuals with two rare al-
leles with the baseline group of heterozygous and homozygous 
subjects. The additive model assumes that there is a linear gradient 
in risk between the three genotypes. Categorical variable are ex-
pressed as frequencies and percentages. Unless otherwise indi-
cated, data are given as median values and ranges. Comparisons of 
continuous variables between patients and controls or among ge-
notypes were performed by the non-parametric Mann–Whitney 
U- or Kruskal-Wallis- test. The association of polymorphisms that 
were significantly associated to stroke with Hcy plasma levels was 
estimated by general linear model adjusted for sex, gender, hyper-
tension, diabetes mellitus, dyslipidaemia, smoking habit. Multiple 
logistic regression analysis was used to estimate odds ratios (OR) 
and 95% confidence intervals (CI) for ischaemic stroke. In the 
multiple analysis, ORs were adjusted for sex, gender, hypertension, 
diabetes mellitus, dyslipidaemia, and smoking habit. In order to re-
duce the type I error, we applied the false discovery rate (FDR) 
multiple testing correction in the statistical analyses. A value of 
p<0.05 was chosen as the cut-off level for statistical significance. 
Haplotype analysis 
In order to prepare datafiles for linkage disequilibrium (LD) and 
haplotype reconstruction analysis, datafiles were processed in R 
environment (http://www.r-project.org). Pairwise LD was evalu-
ated by using SNPAlyze software (Dynacom, Kanagawa, Japan). 
Haplotype reconstruction and frequency estimation were inde-
pendently performed using the PHASE v2.1 software (19), and R 
package haplo.stats by Expectation-Maximization strategy (EM 
algorithm). The haplo.stats package was also used to identify stat-
istically significant associations between haplotypes and disease 
risks by means of generalized linear models. In order to reduce the 
type I error, we applied the false discovery rate (FDR) multiple test-
ing correction in generalised linear model analysis. 
To evaluate the effect of haplotype combination and interaction 
between two unlinked regions we used an algorithm implemented 
in FAMHAP software v16 (20, 21). The FAMHAP interaction 
analysis does not explicitly test for a specific pre-defined inter-
action model, but tests for the global hypothesis that none of the 
considered haplotype interactions shows association with the dis-
ease. The algorithm applies multiple testing correction via the 
minP approach (the p-value of the best marker/region configur-
ation is corrected via Monte-Carlo simulations) (21). 
Results 
Subjects 
Demographic and clinical characteristics of investigated patients 
and subjects are reported in Table 1. 
Single SNP analysis 
In Table 2 genotype distributions of all SNP and Chi2 analysis by 
additive and dominant/recessive models are reported. Genotype 
distribution was significantly different between patients and con-
trols by using the two models for the following SNPs: rs10037045 
BHMT, rs682985 BHMT2, rs1051319 CBS, rs202680 FOLH1, 
rs2274976 MTHFR, rs1979277 SHMT1, rs20721958 TCN2 (Table 
2). 
On multiple logistic regression analysis with stroke as depend-
ent variable and hypertension, diabetes mellitus, dyslipidaemia, 
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 Controls 
(N=1211) 
Stroke patients 
(N=501) 
P-value 
Age 44.0 (12–65) 44.0 (1–65) 0.659 
Sex (male), N (%) 543 (44.8) 228 (45.5) 0.800 
Smoking habit, N (%) 316 (26.1) 199 (39.7) <0.0001 
Diabetes, N (%) 4 (0.3) 11 (2.2) <0.0001 
Hypertension, N (%) 88 (7.3) 141 (28.1) <0.0001 
Dyslipidaemia, N (%) 42 (3.5) 105 (20.9) <0.0001 
BMI, (kg/m2) 23.7 (15.7–45.2) 24.2 (16.5–56.1) 0.029 
BMI, body mass index. 
Table 1: Demographic and clinical characteristics of patients with is-
chaemic stroke and controls. 
Thrombosis and Haemostasis 104.2/2010 © Schattauer 2010
234 Giusti et al. Ischaemic stroke and methionine metabolism genes
Gene dbSNP ID or 
SNP name 
Genotypes (%) Minor allele 
frequency 
P* P°,§ 
Patients (n=501) 
AHCY rs819146 AA(73.5) CC(1.5) C=0.136 0.117 0.039§ 
rs7271501 CC(97.4) GG(0.0) G=0.006 0.087 - 
BHMT rs651852 CC(32.4) TT(21.1) T=0.463 0.260 0.113° 
rs567754 CC(44.3) TT(12.1) T=0.349 0.777 0.491° 
rs10037045 AA(32.6) TT(12.1) T=0.359 0.048 0.017° 
rs585800 AA(61.7) TT(4.4) T=0.209 0.903 0.493° 
BHMT2 rs644191 AA(71.0) GG(2.5) G=0.161 0.689 0.390§ 
rs682985 TT(34.7) CC(16.3) C=0.413 0.039 0.026§ 
AC(23.5) 
CG(2.6) 
CT(48.6) 
CT(43.7) 
AT(52.5) 
AT(34.1) 
AG(27.3) 
TC(44.5) 
CC(3.0) 
GG(0.0) 
TT(19.1) 
TT(12.0) 
TT(14.9) 
TT(4.2) 
GG(1.7) 
CC(20.8) 
Minor allele  
frequency 
C=0.148 
G=0.047 
T=0.434 
T=0.338 
T=0.412 
T=0.213 
G=0.154 
C=0.430 
Genotypes (%) 
Healthy subjects (n=1,211) 
AA(74.2) 
CC(98.6) 
CC(28.5) 
CC(42.3) 
AA(40.2) 
AA(62.6) 
AA(70.3) 
TT(33.6) 
AC(24.3) 
CG(1.4) 
CT(50.4) 
CT(45.6) 
AT(47.7) 
AT(33.0) 
AG(27.2) 
TC(50.1) 
CBS Pro88Ser CC(99.4) CT(0.6) TT(0.0) T=0.003 CC(98.9) CT(1.1) TT(0.0) T=0.005 0.353 - 
Ala114Val CC(99.3) CT(0.5) TT(0.2) T=0.005 CC(97.3) CT(1.8) TT(0.9) T=0.018 0.055 0.017° 
Gly116Arg GG(100.0) GA(0.0) AA(0.0) A=0.000 GG(99.9) GA(0.1) AA(0.0) A=0.000 0.520 - 
rs1051319 GG(71.2) GC(24.2) CC(4.5) C=0.167 GG(77.2) GC(21.2) CC(1.6) C=0.122 <0.0001 <0.0001§ 
ENOSF1 rs8423 CC(36.3) CA(49.3) AA(14.3) A=0.390 CC(34.6) CA(49.6) AA(15.8) A=0.406 0.683 0.465§ 
FOLH1 rs202676 AA(69.5) AG(28.4) GG(2.1) G=0.164 AA(70.4) AG(27.6) GG(2.0) G=0.158 0.904 0.688° 
rs202680 TT(42.9) AT(42.1) AA(15.0) A=0.360 TT(62.2) AT(32.1) AA(5.7) A=0.218 <0.0001 <0.0001°§ 
MTHFD1 rs2357481 AA(99.0) AT(1.0) TT(0.0) T=0.005 AA(99.7) AT(0.3) TT(0.0) T=0.001 0.082 - 
rs1076991 TT(28.7) TC(49.5) CC(21.8) C=0.465 TT(27.8) TC(50.5) CC(21.7) C=0.470 0.904 0.676° 
rs3783732 AA(98.6) AT(1.4) TT(0.0) T=0.007 AA(99.4) AT(0.5) TT(0.1) T=0.003 0.120 0.087° 
rs8003379 AA(58.1) AC(35.6) CC(6.4) C=0.242 AA(53.5) AC(39.6) CC(6.9) C=0.267 0.221 0.084° 
rs1950902 CC(72.9) CT(25.1) TT(2.0) T=0.146 CC(75.5) CT(22.8) TT(1.7) T=0.131 0.522 0.256° 
rs4902283 CC(99.2) CT(0.8) TT(0.0) T=0.004 CC(99.4) CT(0.6) TT(0.0) T=0.003 0.604 - 
rs2236225 GG(29.1) GA(51.3) AA(19.6) A=0.452 GG(33.1) GA(48.6) AA(18.3) A=0.426 0.276 0.109° 
MTHFR rs1801133 CC(26.0) CT(47.9) TT(26.1) T=0.501 AA(28.5) CA(48.9) CC(22.6) A=0.471 0.252 0.119§ 
rs1801131 AA(49.5) CA(39.3) CC(11.2) A=0.308 CC(47.2) CT(43.7) TT(9.1) T=0.309 0.168 0.183§ 
rs2274976 CC(94.3) CT(5.7) TT(0.0) T=0.029 CC(92.2) CT(6.50) TT(1.3) T=0.046 0.046 0.012§ 
rs4846049 CC(48.7) CA(41.3) AA(10.0) A=0.306 CC(45.5) CA(44.3) AA(10.2) A=0.324 0.469 0.227° 
MTR rs4659725 CC(34.1) CG(47.9) GG(17.9) G=0.419 CC(33.2) CG(47.4) GG(19.4) G=0.431 0.779 0.489§ 
rs1805087 AA(67.9) AG(29.5) GG(2.6) G=0.174 AA(67.5) AG(29.2) GG(3.3) G=0.179 0.743 0.441§ 
rs2275566 TT(34.7) TC(46.9) CC(18.4) C=0.418 TT(33.2) TC(47.5) CC(19.3) C=0.431 0.801 0.541° 
rs2853522 CC(29.2) CA(49.3) AA(21.5) A=0.462 CC(29.1) CA(50.7) AA(20.2) A=0.456 0.802 0.537§ 
rs6676866 CC(29.2) CA(48.3) AA(22.5) A=0.467 CC(27.3) CA(49.7) AA(23.0) A=0.478 0.747 0.447° 
MTRR rs326118 AA(71.3) AC(25.4) CC(3.3) C=0.161 AA(72.5) AC(24.4) CC(3.1) C=0.153 0.866 0.601° 
rs1801394 AA(27.3) AG(51.7) GG(21.0) G=0.468 AA(26.3) AG(52.5) GG(21.2) G=0.474 0.913 0.669° 
rs1532268 CC(37.3) CT(48.0) TT(14.7) T=0.387 CC(40.0) CT(45.4) TT(14.6) T=0.373 0.574 0.308° 
rs2303080 TT(97.2) TA(2.8) AA(0.0) A=0.014 TT(97.3) TA(2.7) AA(0.0) A=0.014 0.878 - 
rs10064631 GG(99.5) GC(0.5) CC(0.0) C=0.003 GG(99.8) GC(0.2) CC(0.0) C=0.001 0.302 - 
rs16879334 CC(97.1) CG(2.9) GG(0.0) G=0.015 CC(96.9) CG(3.0) GG(0.1) G=0.016 0.831 0.899° 
rs8659 AA(41.5) AT(45.4) TT(13.1) T=0.358 AA(37.3) AT(46.6) TT(16.1) T=0.396 0.194 0.133° 
NNMT rs566775 CC(66.3) CT(30.7) TT(3.0) T=0.184 CC(66.8) CT(30.4) TT(2.8) T=0.180 0.964 0.833§ 
rs10891639 CC(59.9) CA(36.1) AA(4.0) A=0.222 CC(64.8) CA(31.3) AA(3.9) A=0.196 0.196 0.076° 
rs4646335 TT(68.2) TA(28.4) AA(3.4) A=0.176 TT(69.0) TA(27.6) AA(3.4) A=0.172 0.949 0.754° 
rs3819100 TT(51.1) TC(40.8) CC(8.1) C=0.285 TT(54.1) TC(38.3) CC(7.6) C=0.268 0.528 0.259°
Table 2: Genotype distribution and allele frequency of all investigated SNPs in ischaemic stroke and control subjects. 
smoking habit and each polymorphism as independent variables, 
the gene polymorphisms rs10037045 BHMT [OR 1.38 (1.03–2.31 
95%CI), p=0.033 for carriers of the rare allele], rs682985 BHMT2 
[OR 1.46 (1.07–2.00 95%CI), p=0.017 for rare allele homozygous 
subjects], rs1051319 CBS [OR 3.75 (1.86–7.50 95%CI), p<0.0001 
for rare allele homozygous subjects], and rs202680 FOLH1 [OR 
3.00 (2.00–4.48 95%CI), p<0.0001 for rare allele homozygous sub-
jects] were independent risk factors for ischaemic stroke. 
Haplotype analysis 
After haplotype reconstruction, generalised linear model analysis 
adjusted for traditional cardiovascular risk factors showed a statis-
tically significant association between ischaemic stroke and 
BHMT, CBS, FOLH1, MTR, PON2, TCN2 and TYMS haplotypes 
(Table 3). When we also adjusted for traditional cardiovascular 
risk factors and Hcy levels, the association with ischaemic stroke 
remained independent for the following genes: CBS, FOLH1, 
PON2, TYMS (data not shown). 
Haplotype interaction analysis 
In order to evaluate the possible effect of haplotype combination 
between genes, we applied the expectation/maximization algo-
rithm. According to this analysis, significant interactions were ob-
served among haplotypes of the following genes BHMT-CBS, 
BHMT-FOLH1, BHMT-MTR, BHMT-TCN2, BHMT-TYMS, 
CBS-FOLH1, CBS-PON2, FOLH1-MTR, FOLH1-TCN2, 
FOLH1-TYMS, MTR-PON2, MTR-TCN2, PON2-TYMS (see 
Supplementary Table A available online at www.thrombosis-on
line.com). In Table 4 a selection of combinations of haplotypes 
in two different genes with a large difference in the frequency be-
tween patients and controls are reported. 
Hcy levels 
Hcy levels were significantly higher in patients with ischaemic 
stroke than in controls [9.5 (2.7–65.7) μM vs 8.9 (3.9–49.5) μM; 
p=0.003]. On logistic regression analysis – adjusted for hyperten-
sion, diabetes mellitus, dyslipidemia, and smoking habit – Hcy was 
a mild but statistically significant and independent risk factor for 
stroke [OR=1.03 (95%CI 1.01–1.06), p=0.015]. 
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Table 2: Continued 
Gene dbSNP ID or 
SNP name 
Genotypes (%) Minor allele 
frequency 
P* P°,§ 
Patients (n=501) 
rs10418 GG(60.9) AA(5.0) A=0.242 0.216 0.896° 
TYMS rs502396 CC(26.3) TT(22.5) T=0.470 0.565 0.351° 
rs16430 CC(38.2) AA(14.5) A=0.393 0.698 0.407° 
p*= according to the additive model; p°= according to the dominant model; p§= according to the recessive model. AHCY, adenosylhomocysteinase; BHMT, be-
taine-homocysteine methyltransferase; BHMT2, betaine-homocysteine methyltransferase 2; CBS, cystathionine-beta-synthase; ENOSF1, enolase superfamily 
member 1; FOLH1, folate hydrolase 1; MTHFD1, methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate cyclohydrolase, for-
myltetrahydrofolate synthetase; MTHFR, 5,10-methylenetetrahydrofolate reductase (NADPH); MTR, 5-methyltetrahydrofolate-homocysteine methyltransferase; 
MTRR, 5-methyltetrahydrofolate-homocysteine methyltransferase reductase; NNMT, nicotinamide N-methyltransferase; PON1, paraoxonase 1; PON2, paraoxonase 
2; SLC19A1, solute carrier family 19 (folate transporter), member 1; SHMT1, serine hydroxymethyltransferase 1 (soluble); TCN2, transcobalamin II; TYMS, thymidy-
late synthetase. 
GA(33.9) 
CT(49.3) 
CA(47.5) 
AA(5.2) 
TT(24.4) 
AA(14.3) 
Minor allele  
frequency 
A=0.222 
T=0.490 
A=0.381 
Genotypes (%) 
Healthy subjects (n=1,211) 
GG(56.6) 
CC(28.6) 
CC(36.0) 
GA(38.4) 
CT(48.9) 
CA(49.5) 
PON1 rs854660 TT(43.9) TA(44.8) AA(11.3) A=0.337 TT(39.7) TA(45.9) AA(14.4) A=0.373 0.136 0.108° 
rs662 AA(48.1) AG(41.1) GG(10.8) G=0.313 AA(49.9) AG(41.0) GG(9.1) G=0.296 0.519 0.278§ 
rs3917594 GG(100.0) GA(0.0) AA(0.0) A=0.000 GG(99.9) GA(0.1) AA(0.0) A=0.000 0.524 - 
PON2 rs11545941 CC(63.5) CG(33.5) GG(2.9) G=0.198 CC(62.2) CG(34.1) GG(3.7) G=0.208 0.720 0.460§ 
rs6954345 CC(59.1) CG(37.3) GG(3.6) G=0.223 CC(62.5) CG(33.9) GG(3.6) G=0.206 0.386 0.185° 
SLC19A1 rs3177999 TT(34.1) CT(45.3) CC(20.6) C=0.432 TT(30.4) CT(49.6) CC(20.0) C=0.448 0.223 0.129° 
rs1051266 CC(34.5) CT(44.9) TT(20.6) T=0.430 CC(31.0) CT(49.4) TT(19.6) T=0.443 0.211 0.150° 
rs12659 CC(35.9) CT(44.5) TT(19.6) T=0.418 CC(32.0) CT(47.5) TT(20.5) T=0.443 0.282 0.112° 
SHMT1 rs638416 CC(33.1) CG(50.1) GG(16.8) G=0.418 CC(32.5) CG(51.3) GG(16.2) G=0.418 0.901 0.810° 
rs1979277 GG(98.5) GA(1.5) AA(0.0) A=0.008 GG(99.5) GA(0.5) AA(0.0) A=0.002 0.048 - 
TCN2 rs5749131 GG(36.9) GA(48.3) AA(14.8) A=0.389 GG(36.7) GA(49.9) AA(13.4) A=0.383 0.712 0.447§ 
rs1801198 CC(37.5) CG(47.1) GG(15.4) G=0.389 CC(36.9) CG(49.5) GG(13.6) G=0.383 0.520 0.323§ 
rs20721958 TT(96.0) TA(4.0) AA(0.0) A=0.020 TT(99.9) TA(0.1) AA(0.0) A=0.000 <0.0001 - 
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Table 3: Haplotypes reconstruction analysis for each genes and 
analysis of association with ischaemic stroke by using the gener-
alised linear model (adjusted for sex, gender, hypertension, smoking 
habit, dyslipidaemia, diabetes) and by using the false discovery rate 
(FDR) multiple testing correction. In bold are evidenced SNPs that re-
Gene Haplotypes Frequencies  
in control subjects 
Frequencies in stroke 
patients 
Coefficient Standard 
error  
P-values 
AHCY a c 0.858 0.847    
c c 0.136 0.140 –0.003 0.023 1.00 
Rare haplotypes 0.006 0.013 0.108 0.104 0.542 
SNP1=rs819146; SNP2=rs7271501 
BHMT c c a t 0.136 0.132    
c c a a 0.085 0.084 –0.026 0.039 0.954 
c c t a 0.276 0.288 0.010 0.031 1.00 
c t a a 0.033 0.041 0.060 0.058 0.568 
t c a a 0.012 0.003 –0.062 0.113 1.00 
t c a t 0.067 0.059 –0.007 0.045 1.00 
t c t a 0.072 0.089 0.027 0.039 0.919 
t t a a 0.304 0.262 –0.029 0.027 0.557 
Rare haplotypes 0.011 0.038 0.250 0.081 0.004 
SNP1=rs651852; SNP2=rs567754; SNP3=rs1003745; SNP4=rs585800 
BHMT2 a t 0.583 0.565    
a c 0.250 0.281 0.011 0.019 1.00 
g c 0.160 0.153 –0.004 0.023 1.00 
SNP1=rs644191; SNP2=rs682985 
CBS c c g g 0.857 0.818    
c c g c 0.120 0.172 0.072 0.023 0.003 
Rare haplotypes 0.022 0.009 –0.051 0.092 1.00 
SNP1=Pro88Ser; SNP2=Ala114Val; SNP3=Gly116Arg; SNP4=rs1051319 
FOLH1 g a 0.154 0.163    
a a 0.064 0.205 0.225 0.033 2.36x10–11 
a t 0.773 0.629 –0.032 0.022 0.265 
Rare haplotypes 0.008 0.0015 –0.138 0.098 0.289 
SNP1=rs202676; SNP2=rs202680 
MTHFD1 a t a a c c a 0.267 0.261    
a c a a c c a 0.044 0.047 –0.045 0.053 0.746 
a c a a c c g 0.116 0.129 –0.016 0.031 1.00 
a c a a t c a 0.009 0.022 0.132 0.095 0.315 
a c a a t c g 0.036 0.026 –0.046 0.056 0.769 
a c a c c c a 0.085 0.085 –0.008 0.039 1.00 
a c a c c c g 0.169 0.142 –0.035 0.026 0.353 
a t a a c c g 0.180 0.169 –0.003 0.031 1.00 
a t a a t c a 0.014 0.022 0.192 0.116 0.185 
a t a a t c g 0.063 0.069 –0.030 0.041 0.873 
Rare haplotypes 0.013 0.026 0.148 0.087 0.172 
SNP1=rs2357481; SNP2=rs1076991; SNP3=rs3783732; SNP4=rs8003379; SNP5=rs1950902; SNP6=rs49022083; SNP7=rs2236225 
sulted significantly associated with stroke in the single SNP analysis (Table 
2); all SNPs in haplotypes are reported from 5’ to 3’ end of the relative gene; 
*= this SNP is in located at the 3'UTR of the ENOSF1 gene overlapping the 3’ 
end of the TYMS gene. 
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Table 3: Continued 
Gene Haplotypes Frequencies  
in control subjects 
Frequencies in stroke 
patients 
Coefficient Standard 
error  
P-values 
MTHFR c c c a 0.271 0.260    
c a c a 0.016 0.019 0.044 0.068 0.942 
c a c c 0.220 0.192 –0.029 0.024 0.419 
c c t a 0.017 0.016 –0.014 0.068 1.00 
t a c c 0.434 0.464 0.022 0.019 0.508 
Rare haplotypes 0.041 0.046 0.109 0.052 0.062 
SNP1=rs1801133; SNP2=rs1801131; SNP3=rs2274976; SNP4=rs4846049 
MTR g a c a a 0.395 0.403    
c a c a a 0.026 0.012 –0.109 0.052 0.064 
c a t a a 0.041 0.044 0.051 0.044 0.440 
c a t c c 0.329 0.352 –0.011 0.019 1.00 
c g t c c 0.165 0.169 –0.002 0.023 1.00 
g a t c c 0.015 0.003 –0.150 0.067 0.047 
Rare haplotypes 0.029 0.015 –0.093 0.061 0.232 
SNP1=rs4659725; SNP2=rs1805087; SNP3=rs2275566; SNP4=rs2853522; SNP5=rs6676866 
MTRR a g c t g c a 0.235 0.241    
a a c a g g t 0.013 0.013 0.043 0.073 1.00 
a a c t g c t 0.221 0.188 –0.046 0.025 0.127 
a a t t g c a 0.146 0.165 0.019 0.029 0.946 
a g c t g c t 0.020 0.012 –0.143 0.074 0.098 
a g t t g c a 0.210 0.203 –0.043 0.026 0.182 
c a c t g c t 0.129 0.139 –0.008 0.027 1.00 
Rare haplotypes 0.026 0.038 0.055 0.066 0.760 
SNP1=rs326118; SNP2=rs1801394; SNP3=rs1532268; SNP4=rs2303080; SNP5=rs10064631; SNP6=rs16879334; SNP7=rs8659 
NNMT c c t t 0.515 0.511    
c a a c 0.054 0.049 –0.041 0.045 0.683 
c a t c 0.060 0.085 0.063 0.036 0.149 
c a t t 0.062 0.051 –0.029 0.045 0.973 
c c a c 0.096 0.097 0.008 0.031 1.00 
c c t c 0.029 0.021 –0.032 0.072 1.00 
t a a c 0.015 0.023 0.055 0.099 1.00 
t c t c 0.010 0.013 0.029 0.113 1.00 
t c t t 0.145 0.135 –0.0016 0.032 1.00 
Rare haplotypes 0.013 0.015 0.174 0.173 0.593 
SNP1=rs566775; SNP2=rs10891640; SNP3=rs4646335; SNP4=rs3819100 
PON1 t a g 0.335 0.359    
a a g 0.371 0.328 –0.035 0.019 0.130 
t g g 0.287 0.303 –0.003 0.020 1.00 
Rare haplotypes 0.006 0.009 0.082 0.119 0.889 
SNP1=rs854660; SNP2=rs662; SNP3=rs3917594 
PON2 c c 0.792 0.783    
g g 0.205 0.208 0.022 0.020 0.490 
Rare haplotypes 0.002 0.009 0.522 0.176 0.005 
SNP1= rs11545941; SNP2= rs6954345 
Among the haplotypes significantly associated with ischaemic 
stroke (Table 3), only the rare haplotypes of the BHMT gene [coef-
ficient 22.48 (SE 4.86), p<0.0001] and the aa haplotype of the 
FOLH1 gene [coefficient 1.75 (SE 0.59), p=0.003] significantly 
modulated Hcy levels, whereas all the other haplotypes were not 
associated with increased or decreased Hcy levels. 
Discussion 
In this study we demonstrated that haplotypes in seven genes 
(BHMT, CBS, FOLH1, MTR, PON2, TCN2 and TYMS) coding for 
enzymes involved in the methionine metabolism are susceptibility 
factors for ischaemic stroke in a large cohort of patients who devel-
oped premature disease and that their association is only partially 
dependent on the role of haplotypes in modulating Hcy levels. 
Due to the complexity of regulatory mechanisms of methionine 
metabolism, the contemporary evaluation of several polymor-
phisms in different genes was thought to be an efficient tool for 
understanding the genetic bases of stroke. 
Haplotype analysis allowed us to identify alleles in which poly-
morphisms per se associated with the disease were included, but 
haplotypes helped to better identify subjects either at risk or pro-
tected: e.g. for FOLH1 gene, rs 202680 A allele frequency is 0.22 for 
controls and 0.36 for patients, whereas aa haplotype frequency is 
0.064 for controls and 0.205 for patients. This issue could explain, 
at least in part, the frequent inconsistency of data observed also in 
wide study populations concerning the role of SNPs. 
Moreover, even if haplotypes in seven genes were associated 
with an altered susceptibility to ischaemic stroke, only the miscel-
lanea of rare haplotypes in BHMT, PON2, TCN2 and TYMS genes 
were associated with an increased risk of early-onset ischaemic 
stroke. This finding suggests that several different mutations of low 
frequency in these four genes might contribute to an increased risk 
of stroke by altering either their function or their expression. 
A positive association between plasma Hcy and risk of stroke has 
been repeatedly demonstrated by case-control and cohort studies (4, 
5), and our data are in keeping with these observations. At present, 
few data are available on stroke genetic susceptibility sustained by 
polymorphisms in genes known or hypothesised to modulate Hcy 
levels and/or to alter the methionine cycle. Among these polymor-
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Gene Haplotypes Frequencies  
in control subjects 
Frequencies in stroke 
patients 
Coefficient Standard 
error  
P-values 
c c a 0.149 0.144 0.006 0.025 1.00 
t a c 0.015 0.022 0.011 0.070 1.00 
Rare haplotypes  0.002 0.018 0.218 0.089 0.028 
SNP1=rs502396; SNP2=rs16430; SNP3=rs8423* 
SCL19A1 t c c 0.531 0.549    
c t c 0.022 0.024 0.029 0.056 1.00 
c t t 0.421 0.407 –0.008 0.016 1.00 
t c t 0.019 0.010 –0.125 0.062 0.081 
Rare haplotypes 0.006 0.009 0.056 0.095 1.00 
SNP1=rs3177999; SNP2=rs1051266; SNP3=rs12659 
SHMT1 c g 0.573 0.578    
g g 0.425 0.414 –0.021 0.021 0.574 
Rare haplotypes 0.0025 0.007 0.081 0.127 0.940 
SNP1= rs638416; SNP2=rs1979277 
TCNII g c t g 0.338 0.338    
a c t a 0.019 0.015 –0.024 0.069 1.00 
a c t g 0.039 0.024 –0.056 0.054 0.548 
a g t g 0.329 0.332 –0.0016 0.021 1.00 
g c t a 0.214 0.212 –0.024 0.026 0.663 
g g t g 0.050 0.051 –0.045 0.048 0.650 
Rare haplotypes 0.009 0.027 0.225 0.099 0.044 
SNP1=rs5749131; SNP2=rs1801198; SNP3=rs20721958; SNP4=rs10418 
TYMS t c a 0.453 0.461    
c a c 0.379 0.354 –0.009 0.018 1.00
Table 3: Continued 
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Table 4: Selection  
of some interactions 
between haplotypes in 
different genes ob-
tained by haplotype 
interaction analysis. 
 Region1 Stroke CTR OR P-value 
BHMT      0.0296 
T T 0.219 0.268 0.76  
T C 0.032 0.051 0.62  
BHMT      0.0012 
 
A 
A 
 
 
A 
T 
 
 
 
 
 
 
CBS 
 
 
FOLH1 
Region2 
 
 
C 
C 
 
 
C 
C 
 
 
G 
G 
 
 
G 
G 
 
 
 
 
 
C C A A   A T    0.049 0.067 0.72  
C C A A   A A    0.021 0.004 5.99  
C C T A   A A    0.057 0.017 3.54  
C C A T   A A    0.019 0.008 2.47  
T T A A   A T    0.167 0.246 0.61  
T T A A   A A    0.054 0.020 2.82  
T C T A   A A    0.017 0.006 2.97  
T C A T   A T    0.036 0.049 0.71  
BHMT      MTR         0.0071 
C C T A   G A C A A 0.133 0.109 1.25  
C C T A   C G T C C 0.051 0.039 1.31  
C C A T   G A C A A 0.067 0.046 1.49  
T C T A   G A C A A 0.048 0.027 1.85  
T T A A   C A C A A 0.005 0.011 0.41  
T T A A   C A T C C 0.059 0.112 0.50  
BHMT      TCNII         0.0074 
C C A A   G C T A  0.009 0.018 0.53  
C C A T   A G T G  0.059 0.043 1.38  
C T A A   G C T A  0.003 0.012 0.27  
T T A A   A G T G  0.072 0.109 0.64  
T T A A   A C T G  0.003 0.013 0.23  
T C T A   G C T A  0.031 0.014 2.27  
T C T A   G C T G  0.041 0.023 1.86  
BHMT      TYMS         0.0119 
C C A A   C C A   0.005 0.014 0.38  
C C T A   T C A   0.154 0.123 1.30  
T T A A   T C A   0.114 0.140 0.79  
T T A A   C C A   0.032 0.047 0.67  
T T A A   C A C   0.081 0.112 0.70  
T C A T   C A C   0.020 0.030 0.65  
CBS      FOLH1         0.0006 
C C G G   A T    0.527 0.661 0.57  
C C G G   A A    0.171 0.051 3.87  
C C G C   A A    0.030 0.006 5.07  
CBS      PON2         0.0197 
C C G G   G G    0.163 0.199 0.78  
C C G C   C C    0.156 0.092 1.83  
C C G C   G G    0.018 0.029 0.62 
 Region1 Stroke CTR OR P-value 
C A 0.003 0.012 0.21  
C A 0.016 0.008 1.97  
C G 0.042 0.024 1.76  
C G 0.078 0.049 1.64  
C G 0.061 0.047 1.34  
PON2      0.0054 
G G 0.050 0.082 0.59  
*= multiple testing correction has been applied via the minP approach (the p-value of the best marker/region configuration is cor-
rected via Monte-Carlo simulations) (20, 21). 
T 
T 
T 
T 
T 
 
 
A 
A 
C 
C 
C 
 
 
A 
A 
C 
C 
C 
 
 
 
 
 
 
 
 
TYMS 
 
Region2 
 
G 
G 
G 
A 
G 
 
C 
C 
C 
C 
G 
C 
 
A 
T 
T 
T 
T 
T 
 
C 
A 
G 
A 
G 
G 
 
 
 
 
 
 
 
 
 
FOLH1      MTR         0.0026 
A T    : C A C A A 0.011 0.021 0.52  
A T     G A T C C 0.001 0.015 0.08  
A T     G A C A A 0.261 0.307 0.80  
A T     C A T C C 0.203 0.270 0.69  
A T     C A T A A 0.019 0.028 0.68  
A A     G A C A A 0.097 0.022 4.70  
A A     C A T C C 0.075 0.021 3.72  
A A     C A T A A 0.014 0.001 9.87  
A A     C G T C C 0.039 0.012 3.49  
FOLH1      TCNII         0.0304 
A T     G G T G  0.036 0.050 0.70  
A T     A C T G  0.014 0.027 0.52  
A A     A G T G  0.011 0.022 0.47  
A A     G C T G  0.019 0.024 0.78  
G A     G C T G  0.067 0.045 1.53  
FOLH1      TYMS         0.0004 
A T     T C A   0.297 0.335 0.84  
A T     C A C   0.219 0.313 0.62  
A A     T C A   0.089 0.025 3.80  
A A     C C A   0.036 0.008 4.57  
A A     C A C   0.072 0.015 4.94  
MTR      PON2         0.0053 
C A C A A  C C    0.016 0.022 0.73  
G A T C C  C C    0 0.015 0.02  
G A C A A  G G    0.058 0.076 0.76  
G A C C C  C C    0.025 0 291.48  
C G T C C  G G    0.046 0.029 1.58  
MTR      TCNII         0.0114 
C A C A A  G C T G  0.007 0.012 0.57  
G A C A A  G C T G  0.160 0.132 1.25  
C A T C C  A C T G  0.004 0.011 0.36
Table 4: Continued
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phisms, the most studied is the C677T in MTHFR gene (rs1801133) 
(22). Although several studies showed a trend toward an association 
between stroke and C677T or A1298C MTHFR polymorphisms, 
data are inconsistent (22, 23). Even if in our population an associ-
ation between the 677T allele and increased levels of plasma Hcy lev-
els was confirmed (p<0.0001, data not shown), C677T and A1298C 
polymorphisms were not associated with ischaemic stroke. Fur-
thermore, the only MTHFR polymorphism initially associated with 
stroke (rs2274976), lost this association following adjustment for 
traditional cardiovascular risk factors. Also haplotype reconstruc-
tion analysis in the MTHFR gene showed no association between 
MTHFR haplotypes and stroke. On the other hand, only haplotypes 
of two (BHMT and FOLH1) out of seven genes associated with is-
chaemic stroke did modulate Hcy levels. The BHMT gene encodes a 
cytosolic enzyme that serves, next to methionine synthase, as a facili-
tator of methyl group donation for remethylation of Hcy into me-
thionine. Genetic polymorphisms reducing BHMT function may in 
principle lead to hyperhomocyst(e)inaemia, but such a defect has 
not yet been observed. Our data demonstrate a role of BHMT gene 
in altering the susceptibility to stroke, perhaps by modulating Hcy 
levels. Because the FOLH1 gene encodes a type II transmembrane 
glycoprotein acting as a glutamate carboxypeptidase, an altered 
function of this enzyme may be associated with impaired intestinal 
absorption of dietary folates, resulting in low blood folate and hence 
to hyperhomocysteinaemia. The rs202680, found to be associated 
per se or in haplotype with ischaemic stroke, is a samesense poly-
morphism that shows no linkage disequilibrium with other known 
FOLH1 polymorphisms in coding and regulatory regions. The aa 
haplotype of the FOLH1 gene, that was found to be a strong inde-
pendent risk factor for stroke, is also associated with increased Hcy 
levels. 
Pertaining to the other genes, haplotypes that were associated 
with stroke did not change Hcy levels. These data suggest that ha-
plotypes of genes of the methionine metabolism play an important 
role in stroke development independently of their role in influenc-
ing Hcy and Hcy-thiolactone levels (13) and that perhaps they act 
by altering DNA methylation, genetic stability, and gene ex-
pression (14). For instance the TYMS gene codes an enzyme that 
catalyses the methylation of deoxyuridylate to deoxythymidylate 
using 5,10-methylenetetrahydrofolate (methylene-THF) as a co-
factor, a fundamental reaction to maintain the dTMP pool critical 
for DNA replication and repair. The PON2 gene encodes a protein 
ubiquitously expressed in human tissues that may act as a cellular 
antioxidant, protecting cells from oxidative stress. 
Recently, by evaluating the same panel of polymorphisms, we 
demonstrated that haplotypes in AHCY, FOLH1, MTHFD1, MTR, 
NNMT, PON1 and TYMS genes are susceptibility factors for ab-
dominal aortic aneurysm and that this association is independent 
from their role in modulating Hcy levels (17). The FOLH1 aa ha-
plotype only was a risk factor for both ischaemic stroke and ab-
dominal aortic aneurysm. Perhaps association of the FOLH1 gene 
with stroke and abdominal aortic aneurysm is part of the common 
atherosclerotic mechanisms that underlie the two diseases. 
All gene associations found in abdominal aortic aneurysm are 
independent of the role of haplotypes in modulating Hcy levels, 
whereas in this study at least two haplotypes associated with is-
chaemic stroke did indeed modulate Hcy levels (BHMT rare ha-
plotypes and FOLH1 aa haplotype). This issue seems of particular 
interest if we consider that ischaemic stroke is the only atherot-
rombotic disease for which the effect of folic acid supplementation 
on the risk of stroke is probably causal (24). 
Due to the lack of information about vitamin status, our study 
cannot definitively establish whether susceptibility to stroke con-
ferred by polymorphisms and haplotypes of genes involved in me-
thionine metabolism are dependent from Hcy levels. On the other 
hand, these results are not influenced by folic acid food supple-
mentation, that is not regularly implemented in Italy. 
Patients enrolled in this study were stroke survivors referred to 
our attention at a median time interval between the ischaemic 
stroke and blood sampling of six months. Therefore, we cannot ex-
clude a possible bias due to the loss of died or permanently dis-
abled severe patients. 
The present paper lacks of a data replication in an independent 
cohort. This issue represents a weakness in genetic association 
studies because results could not be confirmed in other popu-
lations. 
Conclusions 
In conclusion, these data have identified novel genetic markers of 
early-onset ischaemic stroke. The deregulation of the methionine 
metabolism due to polymorphisms/haplotypes and therefore the 
association with the premature ischaemic stroke is perhaps due not 
only to their effect on Hcy levels but also to the alteration of the nu-
merous biological processes in which methionine metabolism 
plays a crucial role. 
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What is known about this topic? 
● A positive association exists between plasma homocysteine and 
risk of stroke. 
● Randomised controlled trials performed to date have failed to 
demonstrate that lowering by means of B vitamins reduces the risk 
of stroke. 
What does this paper add? 
● This paper has identified novel genetic markers associated with 
premature stroke in seven genes involved in the homocysteine 
metabolic pathway. 
● The previously recognised link between elevated total homocys-
teine and stroke may be mediated by upstream mechanisms in-
volved in the homocysteine metabolic pathway. 
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